Cargando…
Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors’ IgG1 clonal responses f...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568977/ https://www.ncbi.nlm.nih.gov/pubmed/36243713 http://dx.doi.org/10.1038/s41467-022-33899-1 |
_version_ | 1784809763642540032 |
---|---|
author | van Rijswijck, Danique M. H. Bondt, Albert Hoek, Max van der Straten, Karlijn Caniels, Tom G. Poniman, Meliawati Eggink, Dirk Reusken, Chantal de Bree, Godelieve J. Sanders, Rogier W. van Gils, Marit J. Heck, Albert J. R. |
author_facet | van Rijswijck, Danique M. H. Bondt, Albert Hoek, Max van der Straten, Karlijn Caniels, Tom G. Poniman, Meliawati Eggink, Dirk Reusken, Chantal de Bree, Godelieve J. Sanders, Rogier W. van Gils, Marit J. Heck, Albert J. R. |
author_sort | van Rijswijck, Danique M. H. |
collection | PubMed |
description | Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors’ IgG1 clonal responses following a SARS-CoV-2 infection. We monitor the plasma clonal IgG1 profiles of 8 donors who had experienced an infection by either the wild type Wuhan Hu-1 virus or one of 3 VOCs (Alpha, Beta and Gamma). In these donors we chart the full plasma IgG1 repertoires as well as the IgG1 repertoires targeting the SARS-CoV-2 spike protein trimer VOC antigens. The plasma of each donor contains numerous anti-spike IgG1 antibodies, accounting for <0.1% up to almost 10% of all IgG1s. Some of these antibodies are VOC-specific whereas others do recognize multiple or even all VOCs. We show that in these polyclonal responses, each clone exhibits a distinct cross-reactivity and also distinct virus neutralization capacity. These observations support the need for a more personalized look at the antibody clonal responses to infectious diseases. |
format | Online Article Text |
id | pubmed-9568977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-95689772022-10-16 Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern van Rijswijck, Danique M. H. Bondt, Albert Hoek, Max van der Straten, Karlijn Caniels, Tom G. Poniman, Meliawati Eggink, Dirk Reusken, Chantal de Bree, Godelieve J. Sanders, Rogier W. van Gils, Marit J. Heck, Albert J. R. Nat Commun Article Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors’ IgG1 clonal responses following a SARS-CoV-2 infection. We monitor the plasma clonal IgG1 profiles of 8 donors who had experienced an infection by either the wild type Wuhan Hu-1 virus or one of 3 VOCs (Alpha, Beta and Gamma). In these donors we chart the full plasma IgG1 repertoires as well as the IgG1 repertoires targeting the SARS-CoV-2 spike protein trimer VOC antigens. The plasma of each donor contains numerous anti-spike IgG1 antibodies, accounting for <0.1% up to almost 10% of all IgG1s. Some of these antibodies are VOC-specific whereas others do recognize multiple or even all VOCs. We show that in these polyclonal responses, each clone exhibits a distinct cross-reactivity and also distinct virus neutralization capacity. These observations support the need for a more personalized look at the antibody clonal responses to infectious diseases. Nature Publishing Group UK 2022-10-15 /pmc/articles/PMC9568977/ /pubmed/36243713 http://dx.doi.org/10.1038/s41467-022-33899-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article van Rijswijck, Danique M. H. Bondt, Albert Hoek, Max van der Straten, Karlijn Caniels, Tom G. Poniman, Meliawati Eggink, Dirk Reusken, Chantal de Bree, Godelieve J. Sanders, Rogier W. van Gils, Marit J. Heck, Albert J. R. Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern |
title | Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern |
title_full | Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern |
title_fullStr | Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern |
title_full_unstemmed | Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern |
title_short | Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern |
title_sort | discriminating cross-reactivity in polyclonal igg1 responses against sars-cov-2 variants of concern |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568977/ https://www.ncbi.nlm.nih.gov/pubmed/36243713 http://dx.doi.org/10.1038/s41467-022-33899-1 |
work_keys_str_mv | AT vanrijswijckdaniquemh discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT bondtalbert discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT hoekmax discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT vanderstratenkarlijn discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT canielstomg discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT ponimanmeliawati discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT egginkdirk discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT reuskenchantal discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT debreegodelievej discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT sandersrogierw discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT vangilsmaritj discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern AT heckalbertjr discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern |